Humana price target raised to $300 from $264 at Cantor Fitzgerald
Cantor Fitzgerald analyst Sarah James raised the firm's price target on Humana to $300 from $264 and keeps a Neutral rating on the shares. Cantor prefers payors over providers heading into Q2 earnings, supported by management discussions, proprietary checks, and investor conversations, the analyst tells investors in a